46例前列腺癌患者的组织DNA及血液ctDNA测序分析

唐堂; 唐朋; 谭信韬; 冉强; 彭松; 刘秋礼; 徐静; 江军

doi:10.16016/j.1000-5404.202104084

您当前的位置：

首页 >

文章列表页 >

46例前列腺癌患者的组织DNA及血液ctDNA测序分析

基础医学 | 更新时间：2026-01-09

- 46例前列腺癌患者的组织DNA及血液ctDNA测序分析
- Sequencing analysis on tissue DNA and blood ctDNA from 46 patients with prostate cancer
- 第三军医大学学报 2021年43卷第17期页码：1658-1666, 封3
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家自然科学基金青年科学基金项目(81802558);陆军军医大学科研项目(2017XYY07)
- DOI：10.16016/j.1000-5404.202104084
  中图分类号：
- 收稿：2021-04-14，
  
  纸质出版：2021-09-15
- 稿件说明：
移动端阅览
唐堂, 唐朋, 谭信韬, 等. 46例前列腺癌患者的组织DNA及血液ctDNA测序分析[J]. 第三军医大学学报, 2021,43(17):1658-1666, 封3.

Tang TANG, Peng TANG, Xintao TAN, et al. Sequencing analysis on tissue DNA and blood ctDNA from 46 patients with prostate cancer[J]. Journal of Third Military Medical University, 2021, 43(17): 1658-1666, 封3.
唐堂, 唐朋, 谭信韬, 等. 46例前列腺癌患者的组织DNA及血液ctDNA测序分析[J]. 第三军医大学学报, 2021,43(17):1658-1666, 封3. DOI： 10.16016/j.1000-5404.202104084.

Tang TANG, Peng TANG, Xintao TAN, et al. Sequencing analysis on tissue DNA and blood ctDNA from 46 patients with prostate cancer[J]. Journal of Third Military Medical University, 2021, 43(17): 1658-1666, 封3. DOI： 10.16016/j.1000-5404.202104084.

摘要

目的

探讨前列腺癌患者组织DNA与血液ctDNA检出的突变情况，分析基因突变与临床特点和治疗的相关性。

方法

采用探针杂交捕获和Illumina高通量测序为基础的靶向二代测序技术检测本院泌尿外科46例病理诊断明确的前列腺癌患者的前列腺组织标本（n=31）以及外周血液标本（n=32）循环肿瘤细胞DNA(circulating tumor DNA，ctDNA)的突变情况，检测范围包括1 021个基因的全外显子区域及部分内含子区域中的4种突变类型（点突变、小片段的插入缺失、拷贝数变异和目前已知的融合基因）。

结果

在31例患者的前列腺组织标本中最常被检出的突变基因为TP53（29%，9/31），其次为CDK12（22.6%，7/31）、FOXA1（22.6%，7/31）与JAK1（16.1%，5/31）。在32例外周血ctDNA标本中检测出的常见突变基因为AR（34.3%，11/32）、APC（25%，8/32）、CDK12（18.8%，6/32）、DNMT3a（18.8%，6/32）与TP53（18.8%，6/32）。TMPRSS2-ERG融合基因在所有检测患者中检出率为13%(6/46)。其中1例患者同时存在TMPRSS2-ERG、VEGFA-TMPRSS2及ERG-VEGFA融合突变。46例患者中同源重组相关基因的体细胞突变检出率为21.7%，携带有胚系同源重组基因突变患者占8.7%。且携带（无论胚系或体细胞）同源重组基因突变患者的发病年龄更低、Gleason评分更高、转移灶数量更多，特别是携带胚系突变的患者更显著。

结论

血液ctDNA和传统的组织DNA样本均可检出基因突变；血液ctDNA检测可动态监控前列腺癌基因频谱在治疗过程中的变化，有助于及时调整治疗方案。

Abstract

Objective

To investigate the mutations in the tissue DNA and plasma circulating tumor DNA (ctDNA) from patients with prostate cancer

and analyze their association with clinical characteristics and treatment.

Methods

Based on probe hybridization capture and Illumina high-throughput sequencing

a targeted second-generation sequencing was used to analyze the mutations in 31 tumor tissues and 32 peripheral blood specimens from 46 patients with pathologically diagnosed prostate cancer. The tumor tissues and peripheral blood specimens were sequenced in the whole exons area and part of the introns area of 1 021 genes for 4 types of mutations (point mutation

loss/insert of small fragments

copy number variation and currently known fusion genes).

Results

The most frequently mutated gene was TP53 (29.0%

9/31)

followed by CDK12 (22.6%

7/31)

FOXA1 (22.6%

7/31) and JAK1 (16.1%

5/31) in 31 tissue samples. The most common mutant genes in the 32 blood samples were AR (34.3%

11/32)

APC (25.0%

8/32)

CDK12 (18.8%

6/32)

DNMT3a (18.8%

6/32) and TP53 (18.8%

6/32). TMPRSS2-ERG fusion gene was detected in 13.0% (6/46) of the 46 patients. One patient had TMPRSS2-ERG

VEGFA-TMPRSS2

and ERG-VEGFA fusion mutations simultaneously. The somatic mutation of homologous recombination (HR) associated genes were found in 21.7% (10/46) of all the patients

and those with germline mutations in the HR gene accounted for 8.7% (4/46) of all the patients. Moreover

the patients with HR gene mutations (either germline or somatic)

especially those with germline mutations

had younger onset-age

higher Gleason score

and more metastases.

Conclusion

Gene mutation can be detected from both blood ctDNA and traditional tissue DNA. Dynamic blood ctDNA testing can monitor the changes in gene spectrum of prostate cancer

and is helpful to adjust treatment scheme in time.

关键词

Keywords

references

FERLAY J COLOMBET M SOERJOMATARAM I Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 Eur J Cancer 2018 103 356 387 10.1016/j.ejca.2018.07.005 FERLAY J, COLOMBET M, SOERJOMATARAM I, et al . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018[J ] . Eur J Cancer, 2018, 103: 356-387. DOI: 10.1016/j.ejca.2018.07.005.

TEOH J Y C HIRAI H W HO J M W Global incidence of prostate cancer in developing and developed countries with changing age structures PLoS ONE 2019 14 10 e0221775 10.1371/journal.pone.0221775 TEOH J Y C, HIRAI H W, HO J M W, et al . Globa l incidence of prostate cancer in developing and developed countries with changing age structures[J ] . PLoS ONE, 2019, 14(10): e0221775. DOI: 10.1371/journal.pone.0221775.

PANG C GUAN Y Y LI H B Urologic cancer in China Jpn J Clin Oncol 2016 46 6 497 501 10.1093/jjco/hyw034 PANG C, GUAN Y Y, LI H B, et al . Urologic cancer in China[J ] . Jpn J Clin Oncol, 2016, 46(6): 497-501. DOI: 10.1093/jjco/hyw034.

STRATTON M R CAMPBELL P J FUTREAL P A The cancer genome Nature 2009 458 7239 719 724 10.1038/nature07943 STRATTON M R, CAMPBELL P J, FUTREAL P A. The cancer genome[J]. Nature, 2009, 458(7239): 719-724. DOI: 10.1038/nature07943.

MA X LIU Y LIU Y Pan-cancer genome and transcriptome analyses of 1, 699 paediatric leukaemias and solid tumours Nature 2018 555 7696 371 376 10.1038/nature25795 MA X, LIU Y, LIU Y, et al . Pan-cancer genome and transcriptome analyses of 1, 699 paediatric leukaemias and solid tumours[J ] . Nature, 2018, 555(7696): 371-376. DOI: 10.1038/nature25795.

MARSHALL C H FU W WANG H Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage Prostate Cancer Prostatic Dis 2019 22 1 59 65 10.1038/s41391-018-0086-1 MARSHALL C H, FU W, WANG H, et al . Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage[J ] . Prostate Cancer Prostatic Dis, 2019, 22(1): 59-65. DOI: 10.1038/s41391-018-0086-1.

LIU J N NEAR A CHIARAPPA J A Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data J Med Econ 2019 22 10 1080 1087 10.1080/13696998.2019.1649267 LIU J N, NEAR A, CHIARAPPA J A, et al . Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data[J ] . J Med Econ, 2019, 22(10): 1080-1087. DOI: 10.1080/13696998.2019.1649267.

HAMID A A GRAY K P SHAW G Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer Eur Urol 2019 76 1 89 97 10.1016/j.eururo.2018.11.045 HAMID A A, GRAY K P, SHAW G, et al . Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer[J ] . Eur Urol, 2019, 76(1): 89-97. DOI: 10.1016/j.eururo.2018.11.045.

TOMLINS S A RHODES D R PERNER S Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 2005 310 5748 644 648 10.1126/science.1117679 TOMLINS S A, RHODES D R, PERNER S, et al . Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate canc er[J ] . Science, 2005, 310(5748): 644-648. DOI: 10.1126/science.1117679.

DALL'ERA M A MCPHERSON J D GAO A C Germline and somatic DNA repair gene alterations in prostate cancer Cancer 2020 126 13 2980 2985 10.1002/cncr.32908 DALL'ERA M A, MCPHERSON J D, GAO A C, et al . Germline and somatic DNA repair gene alterations in prostate cancer[J ] . Cancer, 2020, 126(13): 2980-2985. DOI: 10.1002/cncr.32908.

RANTAPERO T WAHLFORS T KÄHLER A Inherited DNA repair gene mutations in men with lethal prostate cancer Genes (Basel) 2020 11 3 E314 10.3390/genes11030314 RANTAPERO T, WAHLFORS T, KÄHLER A, et al . Inherited DNA repair gene mutations in men with lethal prostate cancer[J ] . Genes (Basel), 2020, 11(3): E314. DOI: 10.3390/genes11030314.

MARSHALL C H ANTONARAKIS E S Therapeutic targeting of the DNA damage response in prostate cancer Curr Opin Oncol 2020 32 3 216 222 10.1097/cco.0000000000000617 MARSHALL C H, ANTONARAKIS E S. Therapeutic targeting of the DNA damage response in prostate cancer[J]. Curr Opin Oncol, 2020, 32(3): 216-222. DOI: 10.1097/cco.0000000000000617.

CASTRO E GOH C OLMOS D Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer J Clin Oncol 2013 31 14 1748 1757 10.1200/JCO.2012.43.1882 CASTRO E, GOH C, OLMOS D, et al . Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer[J ] . J Clin Oncol, 2013, 31(14): 1748-1757. DOI: 10.1200/JCO.2012.43.1882.

RIMAR K J TRAN P T MATULEWICZ R S The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies Cancer 2017 123 11 1912 1924 10.1002/cncr.30631 RIMAR K J, TRAN P T, MATULEWICZ R S, et al . The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies[J ] . Cancer, 2017, 123(11): 1912-1924. DOI: 10.1002/cncr.30631.

ZHAO E Y SHEN Y Q PLEASANCE E Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer Clin Cancer Res 2017 23 24 7521 7530 10.1158/1078-0432.CCR-17-1941 ZHAO E Y, SHEN Y Q, PLEASANCE E, et al . Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer[J ] . Clin Cancer Res, 2017, 23(24): 7521-7530. DOI: 10.1158/1078-0432.CCR-17-1941.

MOHLER J L ANTONARAKIS E S ARMSTRONG A J Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 2019 17 5 479 505 10.6004/jnccn.2019.0023 MOHLER J L, ANTONARAKIS E S, ARMSTRONG A J, et al . Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology[J ] . J Natl Compr Canc Netw, 2019, 17(5): 479-505. DOI: 10.6004/jnccn.2019.0023.

LORENTE D OMLIN A ZAFEIRIOU Z Castration-resistant prostate cancer tissue acquisition from bone metastases for molecular analyses Clin Genitourin Cancer 2016 14 6 485 493 10.1016/j.clgc.2016.04.016 LORENTE D, OMLIN A, ZAFEIRIOU Z, et al . Castration-resistant prostate cancer tissue acquisition from bone metastases for molecular analyses[J ] . Clin Genitourin Cancer, 2016, 14(6): 485-493. DOI: 10.1016/j.clgc.2016.04.016.

SAILER V SCHIFFMAN M H KOSSAI M Bone biopsy protocol for advanced prostate cancer in the era of precision medicine Cancer 2018 124 5 1008 1015 10.1002/cncr.31173 SAILER V, SCHIFFMAN M H, KOSSAI M, et al . Bone biopsy protocol for advanced prostate cancer in the era of precision medicine[J ] . Cancer, 2018, 124(5): 1008-1015. DOI: 10.1002/cncr.31173.

WEI Y WU J L GU W J Germline DNA repair gene mutation landscape in Chinese prostate cancer patients Eur Urol 2019 76 3 280 283 10.1016/j.eururo.2019.06.004 WEI Y, WU J L, GU W J, et al . Germline DNA repair gene mutation landscape in Chinese prostate cancer patients[J ] . Eur Urol, 2019, 76(3): 280-283. DOI: 10.1016/j.eururo.2019.06.004.

LITTON J K RUGO H S ETTL J Talazoparib in patients with advanced breast cancer and a germline BRCA mutation N Engl J Med 2018 379 8 753 763 10.1056/nejmoa1802905 LITTON J K, RUGO H S, ETTL J, et al . Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J ] . N Engl J Med, 2018, 379(8): 753-763. DOI: 10.1056/nejmoa1802905.

GOLAN T HAMMEL P RENI M Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer N Engl J Med 2019 381 4 317 327 10.1056/NEJMoa1903387 GOLAN T, HAMMEL P, RENI M, et al . Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J ] . N Engl J Med, 2019, 381(4): 317-327. DOI: 10.1056/NEJMoa1903387.

LEDERMANN J A DREW Y KRISTELEIT R S Homologous recombination deficiency and ovarian cancer Eur J Cancer 2016 60 49 58 10.1016/j.ejca.2016.03.005 LEDERMANN J A, DREW Y, KRISTELEIT R S. Homologous recombination deficiency and ovarian cancer[J]. Eur J Cancer, 2016, 60: 49-58. DOI: 10.1016/j.ejca.2016.03.005.

WONG-BROWN M W MELDRUM C J CARPENTER J E Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer Breast Cancer Res Treat 2015 150 1 71 80 10.1007/s10549-015-3293-7 WONG-BROWN M W, MELDRUM C J, CARPENTER J E, et al . Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer[J ] . Breast Cancer Res Treat, 2015, 150(1): 71-80. DOI: 10.1007/s10549-015-3293-7.

ATTARD G PARKER C EELES R A Prostate cancer Lancet 2016 387 10013 70 82 10.1016/S0140-6736(14)61947-4 ATTARD G, PARKER C, EELES R A, et al . Prostate cancer[J ] . Lancet, 2016, 387(10013): 70-82. DOI: 10.1016/S0140-6736(14)61947-4.

CHENG H H SOKOLOVA A O SCHAEFFER E M Germline and somatic mutations in prostate cancer for the clinician J Natl Compr Cancer Netw 2019 17 5 515 521 10.6004/jnccn.2019.7307 CHENG H H, SOKOLOVA A O, SCHAEFFER E M, et al . Germline and somatic mutations in prostate cancer for the clinician[J ] . J Natl Compr Cancer Netw, 2019, 17(5): 515-521. DOI: 10.6004/jnccn.2019.7307.

CANCER GENOME ATLAS RESEARCH NETWORK The molecular taxonomy of primary prostate cancer Cell 2015 163 4 1011 1025 10.1016/j.cell.2015.10.025 CANCER GENOME ATLAS RESEARCH NETWORK. The molecular taxonomy of primary prostate cancer[J]. Cell, 2015, 163(4): 1011-1025. DOI: 10.1016/j.cell.2015.10.025.

ROBINSON D VAN ALLEN E M WU Y M Integrative clinical genomics of advanced prostate cancer Cell 2015 161 5 1215 1228 10.1016/j.cell.2015.05.001 ROBINSON D, VAN ALLEN E M, WU Y M, et al . Integrative clinical genomics of advanced prostate cancer[J ] . Cell, 2015, 161(5): 1215-1228. DOI: 10.1016/j.cell.2015.05.001.

KU S Y ROSARIO S WANG Y Q Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance Science 2017 355 6320 78 83 10.1126/science.aah4199 KU S Y, ROSARIO S, WANG Y Q, et al . Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance[J ] . Science, 2017, 355(6320): 78-83. DOI: 10.1126/science.aah4199.

PRITCHARD C C MATEO J WALSH M F Inherited DNA-repair gene mutations in men with metastatic prostate cancer N Engl J Med 2016 375 5 443 453 10.1056/nejmoa1603144 PRITCHARD C C, MATEO J, WALSH M F, et al . Inherited DNA-repair gene mutations in men with metastatic prostate cancer[J ] . N Engl J Med , 2016, 375(5): 443-453. DOI: 10.1056/nejmoa1603144.

WU J L WEI Y PAN J Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients Int J Cancer 2021 148 3 673 681 10.1002/ijc.33324 WU J L, WEI Y, PAN J, et al . Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients[J ] . Int J Cancer, 2021, 148(3): 673-681. DOI: 10.1002/ijc.33324.

OH M ALKHUSHAYM N FALLATAH S The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis Prostate 2019 79 8 880 895 10.1002/pros.23795 OH M, ALKHUSHAYM N, FALLATAH S, et al . The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis[J ] . Prostate, 2019, 79(8): 880-895. DOI: 10.1002/pros.23795.

NYBERG T FROST D BARROWDALE D Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study Eur Urol 2020 77 1 24 35 10.1016/j.eururo.2019.08.025 NYBERG T, FROST D, BARROWDALE D, et al . Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study[J ] . Eur Urol, 2020, 77(1): 24-35. DOI: 10.1016/j.eururo.2019.08.025.

KOTE-JARAI Z LEONGAMORNLERT D SAUNDERS E BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients Br J Cancer 2011 105 8 1230 1234 10.1038/bjc.2011.383 KOTE-JARAI Z, LEONGAMORNLERT D, SAUNDERS E, et al . BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients[J ] . Br J Cancer, 2011, 105(8): 1230-1234. DOI: 10.1038/bjc.2011.383.

YADAV S HART S N HU C L Contribution of inherited DNA-repair gene mutations to hormone-sensitive and castrate-resistant metastatic prostate cancer and implications for clinical outcome JCO Precis Oncol 2019 3 PO.19.00067 10.1200/PO.19.00067 YADAV S, HART S N, HU C L, et al . Contribution of inherited DNA-repair gene mutations to hormone-sensitive and castrate-resistant metastatic prostate cancer and implications for clinical outcome[J ] . JCO Precis Oncol, 2019, 3: PO. 19.00067. DOI: 10.1200/PO.19.00067.

CARLSON A S ACEVEDO R I LIM D M Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer PLoS ONE 2020 15 9 e0239686 10.1371/journal.pone.0239686 CARLSON A S, ACEVEDO R I, LIM D M, et al . Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer[J ] . PLoS ONE, 2020, 15(9): e0239686. DOI: 10.1371/journal.pone.0239686.

CHENG H H PRITCHARD C C BOYD T Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer Eur Urol 2016 69 6 992 995 10.1016/j.eururo.2015.11.022 CHENG H H, PRITCHARD C C, BOYD T, et al . Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer[J ] . Eur Urol, 2016, 69(6): 992-995. DOI: 10.1016/j.eururo.2015.11.022.

TANG T WANG L N WANG P Case report: co-existence of BRCA2 and PALB2 germline mutations in familial prostate cancer with solitary lung metastasis Front Oncol 2020 10 564694 10.3389/fonc.2020.564694 TANG T, WANG L N, WANG P, et al . Case report: co-existence of BRCA2 and PALB2 germline mutations in familial prostate cancer with solitary lung metastasis[J ] . Front Oncol, 2020, 10: 564694. DOI: 10.3389/fonc.2020.564694.

KO J M NING L ZHAO X K BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese Int J Cancer 2020 146 4 1042 1051 10.1002/ijc.32619 KO J M, NING L, ZHAO X K, et al . BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese[J ] . Int J Cancer, 2020, 146(4): 1042-1051. DOI: 10.1002/ijc.32619.

MATEO J CARREIRA S SANDHU S DNA-repair defects and olaparib in metastatic prostate cancer N Engl J Med 2015 373 18 1697 1708 10.1056/NEJMoa1506859 MATEO J, CARREIRA S, SANDHU S, et al . DNA-repair defects and olaparib in metastatic prostate cancer[J ] . N Engl J Med, 2015, 373(18): 1697-1708. DOI: 10.1056/NEJMoa1506859.

MATEO J PORTA N BIANCHINI D Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Lancet Oncol 2020 21 1 162 174 10.1016/S1470-2045(19)30684-9 MATEO J, PORTA N, BIANCHINI D, et al . Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial[J ] . Lancet Oncol, 2020, 21(1): 162-174. DOI: 10.1016/S1470-2045(19)30684-9.

CAMPOS-CARRILLO A WEITZEL J N SAHOO P Circulating tumor DNA as an early cancer detection tool Pharmacol Ther 2020 207 107458 10.1016/j.pharmthera.2019.107458 CAMPOS-CARRILLO A, WEITZEL J N, SAHOO P, et al . Circulating tumor DNA as an early cancer detection tool[J ] . Pharmacol Ther, 2020 , 207: 107458. DOI: 10.1016/j.pharmthera.2019.107458.

OELLERICH M SCHÜTZ E BECK J Using circulating cell-free DNA to monitor personalized cancer therapy Crit Rev Clin Lab Sci 2017 54 3 205 218 10.1080/10408363.2017.1299683 OELLERICH M, SCHÜTZ E, BECK J, et al . Using circulating cell-free DNA to monitor personalized cancer therapy[J ] . Crit Rev Clin Lab Sci, 2017, 54(3): 205-218. DOI: 10.1080/10408363.2017.1299683.

NAKAMURA Y YOSHINO T Clinical utility of analyzing circulating tumor DNA in patients with metastatic colorectal cancer Oncologist 2018 23 11 1310 1318 10.1634/theoncologist.2017-0621 NAKAMURA Y, YOSHINO T. Clinical utility of analyzing circulating tumor DNA in patients with metastatic colorectal cancer[J]. Oncologist, 2018, 23(11): 1310-1318. DOI: 10.1634/theoncologist.2017-0621.

WYATT A W ANNALA M AGGARWAL R Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer J Natl Cancer Inst 2017 109 12 djx118 10.1093/jnci/djx118 WYATT A W, ANNALA M, AGGARWAL R, et al . Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer[J ] . J Natl Cancer Inst, 2017, 109(12): djx118. DOI: 10.1093/jnci/djx118.

GOODALL J MATEO J YUAN W Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition Cancer Discov 2017 7 9 1006 1017 10.1158/2159-8290.CD-17-0261 GOODALL J, MATEO J, YUAN W, et al . Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition[J ] . Cancer Discov, 2017, 7(9): 1006-1017. DOI: 10.1158/2159-8290.CD-17-0261.

VOLANTE M TOTA D GIORCELLI J Androgen deprivation modulates gene expression profile along prostate cancer progression Hum Pathol 2016 56 81 88 10.1016/j.humpath.2016.06.004 VOLANTE M, TOTA D, GIORCELLI J, et al . Androgen deprivation modulates gene expression profile along prostate cancer progression[J ] . Hum Pathol, 2016, 56: 81-88. DOI: 10.1016/j.humpath.2016.06.004.

HORNING A M WANG Y LIN C K Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell-cycle-related transcription and attenuated androgen response Cancer Res 2018 78 4 853 864 10.1158/0008-5472.CAN-17-1924 HORNING A M, WANG Y, LIN C K, et al . Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell-cycle-related transcription and attenuated androgen response[J ] . Cancer Res, 2018, 78(4): 853-864. DOI: 10.1158/0008-5472.CAN-17-1924.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

双氢青蒿素诱导前列腺癌细胞焦亡及调控凋亡相关斑点样蛋白甲基化

副交感神经M1受体通过Caspase-1/GSDMD通路调控前列腺癌细胞焦亡

二甲双胍延缓前列腺癌进展的回顾性研究

联合检测P504s和Claudin-4在前列腺癌中的表达及其在预后评估中的价值

交感神经β2肾上腺素受体促进前列腺癌转移并抵抗肿瘤细胞的凋亡